“$LLY — How durable is Lilly's lead in GLP-1 obesity drugs — supply, pricing pressure, the oral pipeline — and how much of it is already priced in?”
- ▸Oral upside — Foundayo ~$98M in Q2 2026 vs injectable tens of billions; Novo oral already live.
- ▸Net price path — Filings already show lower realized prices; Medicare discounts from Jul 1, 2026.
- ▸Supply as moat — Shortages easing industry-wide; capacity is table stakes.
- At the Q3 2026 earnings release on 2026-10-29, Lilly will again characterize Mounjaro/Zepbound growth as driven primarily by increased volume and partially offset by lower realized prices, extending the FY2025 and H1 2026 pattern. open · by Oct 29, 2026
- Lilly Q3 2026 total revenue will be at least $22.1 billion when reported on 2026-10-29, consistent with an intact volume-compounding tirzepatide franchise and the low end of the cited street range. confirmed
- Foundayo (orforglipron) will not become a 2026–27 EPS savior at injectable scale: full-year 2027 Foundayo revenue will remain below $5 billion, in line with a slow 2027–30 oral build versus tirzepatide’s tens of billions. open · by Feb 28, 2028
- Tirzepatide (Mounjaro + Zepbound) will still account for at least 50% of Lilly’s total revenue in FY2026, reflecting sustained—not diminishing—franchise concentration after 56% in FY2025 and 65% in H1 2026. open · by Feb 28, 2027